[Diabetic neuropathy--concept, staging, diagnosis, treatment].
Ida
Masayoshi
M
Department of Neurology, Toranomon Hospital.
Kuroiwa
Yoshiyuki
Y
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D002908:Chronic Disease; D003929:Diabetic Neuropathies / Q000145:classification / Q000175:diagnosis / Q000628:therapy; D003937:Diagnosis, Differential; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005438:Fludrocortisone / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008801:Mexiletine / Q000627:therapeutic use; D020932:Nerve Growth Factor / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D012720:Severity of Illness Index; D014665:Vasodilator Agents / Q000627:therapeutic use; D014805:Vitamin B 12 / Q000627:therapeutic use
D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D014665:Vasodilator Agents; D008801:Mexiletine; D020932:Nerve Growth Factor; D000449:Aldehyde Reductase; D014805:Vitamin B 12; D005438:Fludrocortisone